Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
Abstract Background Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter‐individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly...
Main Authors: | Mirko Signorelli, Burcu Ayoglu, Camilla Johansson, Hanns Lochmüller, Volker Straub, Francesco Muntoni, Erik Niks, Roula Tsonaka, Anja Persson, Annemieke Aartsma‐Rus, Peter Nilsson, Cristina Al‐Khalili Szigyarto, Pietro Spitali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-04-01
|
Series: | Journal of Cachexia, Sarcopenia and Muscle |
Subjects: | |
Online Access: | https://doi.org/10.1002/jcsm.12517 |
Similar Items
-
Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
by: Pietro Spitali, et al.
Published: (2018-08-01) -
Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy
by: Chiara Passarelli, et al.
Published: (2020-07-01) -
Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients
by: Mirko Signorelli, et al.
Published: (2021-04-01) -
Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy
by: Virginie Mariot, et al.
Published: (2020-09-01) -
Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
by: Shefa Tawalbeh, et al.
Published: (2020-10-01)